Diabetes
Guideline | Management of hyperosmolar hyperglycemic state in adults.
15 Nov, 2022 | 13:03h | UTC
M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.
11 Nov, 2022 | 14:04h | UTCCommentaries:
Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News
EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD
Commentary on Twitter
Our SGLT2 Trialists Consortium meta-analysis *the largest ever* in @TheLancet https://t.co/YlWkRQTDAW
Definitive evidence that SGLT2i ⬇️:
– Kidney failure
– AKI
– CV death
– All-cause deathRegardless of diabetes
Led by @NatalieStaplin @RichardHaynes3 @willkidney #AHA22 pic.twitter.com/uAX15mD9XY
— Brendon Neuen (@brendonneuen) November 6, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
M-A | Head-to-head trials comparing sulfonylureas and low hypoglycemic risk antidiabetic drugs.
11 Nov, 2022 | 13:38h | UTC
RCT | Efficacy of a digital behavioral therapeutic application to improve glycemic control in adults with Type 2 DM.
7 Nov, 2022 | 12:33h | UTCCommentary: Smartphone-delivered CBT improves glycemic control in people with type 2 diabetes – medwire News
Crossover RCT | Efficacy of low-dose Empagliflozin as an adjunct to hybrid closed-loop insulin therapy in adults with Type 1 DM.
7 Nov, 2022 | 12:24h | UTCLow-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial – Diabetes Care (link to abstract – $ for full-text)
Study suggests a personalized frequency of urinary albumin screening may be best for patients with Type 1 Diabetes.
3 Nov, 2022 | 13:46h | UTCOptimal Frequency of Urinary Albumin Screening in Type 1 Diabetes – Diabetes Care (link to abstract – $ for full-text)
Development, validation and clinical utility of a risk prediction model for adverse pregnancy outcomes in gestational diabetes.
3 Nov, 2022 | 13:45h | UTC
Commentary on Twitter (thread – click for more)
🧵PeRSonal GDM is a modelling tool that predicts if women with gestational diabetes could have ⬆️ risk of adverse pregnancy outcomes. It's being tested in other groups & developed as an online clinical calculator. New work by @DrShamilCooray @HelenaTeede & team in @eClinicalMed pic.twitter.com/tIyM4KHlre
— MCHRI (@MCHRImonash) September 5, 2022
M-A | Association of SGLT2 inhibitors with cardiovascular outcomes and safety events.
1 Nov, 2022 | 11:56h | UTC
M-A of RCT | Comparison of low carbohydrate vs. low fat diets in Type 2 DM.
31 Oct, 2022 | 13:55h | UTC
RCT | Effects of a low-carbohydrate dietary intervention on hemoglobin A1c.
31 Oct, 2022 | 13:54h | UTCSee also: Visual Abstract
News Release: At risk for diabetes? Cut the carbs, says new study – Tulane University
Commentaries:
Low-Carb Diet Promising for Lowering Blood Sugar in Prediabetes – TCTMD
Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.
31 Oct, 2022 | 13:47h | UTC
M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.
26 Oct, 2022 | 14:32h | UTCCommentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News
KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.
24 Oct, 2022 | 14:16h | UTCRelated: ADA/KDIGO Consensus Report | Diabetes management in chronic kidney disease.
M-A | Safety of sotagliflozin in diabetes mellitus type 1 and type 2.
19 Oct, 2022 | 14:12h | UTC
M-A | Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes.
19 Oct, 2022 | 14:11h | UTC
Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.
18 Oct, 2022 | 12:58h | UTCTrends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)
Related Study: Study shows that the leading causes of hospitalization of adults with diabetes are changing.
RCT | Two-year effects of Semaglutide in adults with overweight or obesity.
18 Oct, 2022 | 12:53h | UTCCommentary: STEP 5: Sustained semaglutide treatment maintains weight loss – medwire News
Related:
RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity
Commentary on Twitter
Results from the STEP 5, testing #semaglutide as an adjuct to behavioral interventions in adults with #overweight or #obesity, demonstrate sustained #weightloss over a period of 104 weeks. @ProfBatterhamMD @seanwharton @DrGeorgiaRigas https://t.co/0mBtzhCYID
— Nature Medicine (@NatureMedicine) October 11, 2022
Cohort Study | Duration of diabetes and use of insulin are the most important predictors of diabetic retinopathy.
13 Oct, 2022 | 13:44h | UTCCommentary: Insulin Use May Predict the Development of Diabetic Retinopathy – HCP Live
Cohort Study | Effect of diabetes on morbidity and mortality in patients with acromegaly.
13 Oct, 2022 | 13:37h | UTC
Commentary on Twitter
Take a look at our new paper in JCEM that further our understanding about diabetes in patients with acromegaly. We show that concomitant diabetes in acromegaly is associated with an added mortality and morbidity risk https://t.co/2OIM0h1WzP #acromegaly #diabetes @EndoSocJournals pic.twitter.com/nOZIpARZwO
— Dr Daniel S. Olsson (@olsson_dr) July 3, 2022
Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.
11 Oct, 2022 | 13:29h | UTCSee also: DIAL Model Calculator
Diabetic kidney disease back in focus: management field guide for health care professionals in the 21st century.
7 Oct, 2022 | 14:08h | UTCRelated: ADA/KDIGO Consensus Report | Diabetes management in chronic kidney disease.
EASD/ADA Consensus Report | Automated insulin delivery: benefits, challenges, and recommendations.
6 Oct, 2022 | 13:46h | UTCAutomated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association – Diabetologia (if the link is paywalled, try this one)
ADA/KDIGO Consensus Report | Diabetes management in chronic kidney disease.
5 Oct, 2022 | 13:59h | UTCNews Release: NEWS RELEASE: ADA & KDIGO Release Joint Consensus Report on Diabetes Management in CKD
Cohort Study | Diabetes diagnosed at younger ages is associated with increased morbidity compared to diagnosis in older adults.
3 Oct, 2022 | 14:02h | UTC
RCT | In patients with Type 1 Diabetes, the use of a “bionic pancreas” reduced HbA1c without increasing hypoglycemia.
29 Sep, 2022 | 13:35h | UTCMulticenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)